JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported initial data from a Phase 2 study for nomlabofusp in ...

Larimar Therapeutics (NASDAQ:LRMR) has had a few hiccups since I last wrote about this biotech. This was in a prior Seeking Alpha article I wrote entitled "Larimar: Friedreich's Ataxia Drug With ...

As of June 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $138.5 million. Together with net proceeds of approximately $65.1 million from the July 2025 public ...

The last time I wrote about Larimar Therapeutics, Inc. (NASDAQ:LRMR) it was in a Seeking Alpha article entitled "Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s Ataxia (FA), reporting key regulatory advancements, ongoing ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Larimar Therapeutics ( (LRMR)) has issued ...